Compare Byrna Technologies Inc (BYRN) vs Mesoblast Limited (MESO) Price & Performance

BYRN trades at $4.25, down 12.37% on the day, reflecting investor reaction to recent earnings misses and revenue declines. The stock shows a bullish technical signal with strong moving average support, but fundamentals are mixed with a negative net income margin of -3.39% and ROE of -6.3% for 2026. Recent management changes and strategic acquisitions aim to revitalize growth amid sales challenges highlighted in Q2 2026 results.

The outlook remains cautious due to execution risks in marketing turnaround and competitive pressures. Analyst consensus is 71% buy, but investors face volatility from ongoing investigations and weak quarterly performance. Upside depends on successful brand repositioning and retail expansion under new leadership.

MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.

Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.